| Turkey | Austria | Spain | |
| Lung biopsy | from $1,500 | ≈ $2,000 | from $4,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Lung biopsy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Lung biopsy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Lung biopsy journey.
Professor Christoph Zielinski is the Chairman of the Vienna Cancer Center. He leads the International Oncology Center at Wiener Privatklinik and specializes in lung cancer care.
Dr. Ari Raphael is a medical oncologist at Sourasky Medical Center in Tel Aviv. He specializes in thoracic malignancies, lung cancer, and breast cancer. Dr. Raphael won the ISCORT research grant competition for his work in oncology. He serves as a senior lecturer at Tel Aviv University.
Dr. Amos Toren is a pediatric hemato-oncologist at Sheba Medical Center. He served as Director of the Pediatric Hemato-Oncology and Bone Marrow Transplant Division. Dr. Toren holds a PhD in Human Genetics. He specializes in CAR T-cell therapy and bone marrow transplantation for children. Forbes Israel has recognized his expertise in hematology.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.